Browse everything: Tickers A–Z · Issuers · Comparisons · Tags
HCM Stock — HUTCHMED DRC
HUTCHMED DRC (HCM)
Updated October 16, 2026.
HCM is a Stock. Total return is 4.9% over the past 10.6 years, 338.6 points behind SPY at 343.5%.
HUTCHMED (China) Limited is a biopharmaceutical company that discovers, develops, and commercializes targeted cancer therapies and immunological disease treatments, with operations spanning Hong Kong, the United States, and other international markets. Its marketed drugs include Fruquintinib for various cancers and Savolitinib for lung and kidney cancers, while its pipeline includes multiple candidates in clinical development across oncology and hematology; the company maintains collaboration agreements with major pharmaceutical partners including AstraZeneca, Eli Lilly, and Takeda. This equity security does not currently pay distributions.
HCM performance versus SPY
Price and return data through 2026-10-16.
Total return is 4.9% over the past 10.6 years, 338.6 points behind SPY at 343.5%. Over the past year its total return — price change plus distributions reinvested — is -8.8%. Its deepest 1-year drawdown was 37.8%.
| Window | Total return | CAGR |
|---|---|---|
| 1M | 4.4% | — |
| 3M | 21.0% | — |
| 6M | -8.5% | — |
| YTD | 5.4% | — |
| 1Y | -8.8% | — |
| 2Y CAGR | — | -15.80% |
| 3Y CAGR | — | -9.20% |
| 5Y CAGR | — | -15.30% |
| 10Y CAGR | — | 2.20% |
| Since inception (10.6 years) | 4.9% | 0.50% |
HCM key facts
- Asset type
- Stock
- Asset class
- Equity
- Inception date
- 03/17/2016
- Distribution frequency
- None
- Last close
- $14.05 (as of 2026-10-16)
- Market cap
- $2,442,089,060
- Average volume
- 22408.0
- Beta
- 0.362
- Payout ratio
- 0.0%
- P/E ratio
- 140.5
- Forward P/E
- 18.0832
- EPS
- $0.10
How Dividend Vision calculates yield and returns
Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.
Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology
Sources and review
Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.
Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.
HCM risks and drawbacks
Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 37.8%.
Who may consider HCM — and who may not
It is a weaker fit for investors who need monthly cash flow (HCM does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.
More on HCM
Frequently asked questions
Does HCM pay monthly?
No. HCM does not currently distribute.
When does HCM pay a dividend?
HCM does not currently distribute.
How has HCM performed?
Total return is 4.9% over the past 10.6 years, 338.6 points behind SPY at 343.5%. Over the past year its total return — price change plus distributions reinvested — is -8.8%. Its deepest 1-year drawdown was 37.8%.
Tickers
Holdings as-of date unavailable.
| Ticker | Name | Weight |
|---|
See how this investment would fit into your portfolio.